Occam Places Chief Development Officer of Groundbreaking Longevity Player, Loyal
In May 2024, Occam recruited Hubert Chen, MD as Chief Development Officer of Loyal, a biotech company pioneering longevity drugs for dogs. Since its founding in 2019, Loyal has raised $125M from blue chip VCs including Bain and Khosla. The company currently has three drugs in development to extend healthy lifespan in dogs and anticipates the most advanced drug will be available in early 2025, pending FDA conditional approval.
Chen brings two decades of translational and clinical development experience within human therapeutics to Loyal’s animal health pipeline. Hubert came to Loyal from Forte Biosciences, where he served as Chief Medical Officer. He was formerly the Chief Medical Officer of metabolic biotech Metacrine and the Chief Scientific and Medical Officer of protein technology platform biotech Pfenex, leading up to its sale to Ligand Pharmaceuticals. Hubert has an MD from Columbia University and a BA from Stanford University.
Occam Global is an executive recruiting and leadership advisory firm with specialties across technological fields including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.